Effect of clinical pharmacy services on patient safety, treatment perception and adherence in patients with acute lymphoblastic leukemia

Impact of Intensified Clinical Pharmacological/ Pharmaceutical care on Patient Safety, Treatment Perception and Adherence in Acute Lymphoblastic Leukaemia - IPCAL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/10/046780

Enrollment

130

Registered

2022-10-26

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]

Interventions

Intervention1: Pharmacological/ pharmaceutical care: A clinical pharmacist will carry out a comprehensive medication reconciliation, and patient will be provided information about ongoing therapy, pot

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with acute Lymphoblastic Leukemia

Exclusion criteria

Exclusion criteria: Patients with MMSE score less than 23 with history of cognitive deficiency

Design outcomes

Primary

Measure	Time frame
Number of drug related problems (side effects and unresolved medication errors according to PCNE classification)Timepoint: 4 weeks for induction phase and 12 weeks for maintenance phase	—

Secondary

Measure	Time frame
Assessment of treatment discontinuation, unscheduled hospital admission and deathTimepoint: 4 weeks for induction phase and 12 weeks for maintenance phase;Event-free survivalTimepoint: 4 weeks for induction phase and 12 weeks for maintenance phase;Improvement in TSQM, MARS, SIMS, QOL scoresTimepoint: 4 weeks for induction phase and 12 weeks for maintenance phase;Incidence and severity of all adverse events (CTCAE more than Grade 2)Timepoint: 4 weeks for induction phase and 12 weeks for maintenance phase;Potential drug-drug interactionsTimepoint: 4 weeks for induction phase and 12 weeks for maintenance phase;Proportion of polypharmacyTimepoint: 4 weeks for induction phase and 12 weeks for maintenance phase	—

Measure

Time frame

Assessment of treatment discontinuation, unscheduled hospital admission and deathTimepoint: 4 weeks for induction phase and 12 weeks for maintenance phase;Event-free survivalTimepoint: 4 weeks for induction phase and 12 weeks for maintenance phase;Improvement in TSQM, MARS, SIMS, QOL scoresTimepoint: 4 weeks for induction phase and 12 weeks for maintenance phase;Incidence and severity of all adverse events (CTCAE more than Grade 2)Timepoint: 4 weeks for induction phase and 12 weeks for maintenance phase;Potential drug-drug interactionsTimepoint: 4 weeks for induction phase and 12 weeks for maintenance phase;Proportion of polypharmacyTimepoint: 4 weeks for induction phase and 12 weeks for maintenance phase

—

Countries

India

Contacts

Public ContactDr Vikram Gota

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

vikramgota@gmail.com02227405493

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026